Base editing of Ptbp1 in neurons alleviates symptoms in a mouse model of Parkinson’s disease
eLife · 2024
DOI: 10.7554/elife.97180 ↗Kurz gefasst
Fachartikel in der Zeitschrift eLife, 2024. Verfasst von Desiree Böck und 10 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Pharmacology and Toxicology, University of Zurich, Zurich, Switzerland. Hauptthemen laut MEDLINE: Polypyrimidine Tract-Binding Protein, Disease Models, Animal, Heterogeneous-Nuclear Ribonucleoproteins, Parkinson Disease. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 92 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Swiss National Science Foundation, Novartis Foundation for Medical-Biological Research, European Research Council.
Abstract (Originalsprache)
Parkinson’s disease (PD) is a multifactorial disease caused by irreversible progressive loss of dopaminergic neurons (DANs). Recent studies have reported the successful conversion of astrocytes into DANs by repressing polypyrimidine tract binding protein 1 (PTBP1), which led to the rescue of motor symptoms in a chemically-induced mouse model of PD. However, follow-up studies have questioned the validity of this astrocyte-to-DAN conversion model. Here, we devised an adenine base editing strategy to downregulate PTBP1 in astrocytes and neurons in a chemically-induced PD mouse model. While PTBP1 downregulation in astrocytes had no effect, PTBP1 downregulation in neurons of the striatum resulted in the expression of the DAN marker tyrosine hydroxylase (TH) in non-dividing neurons, which was associated with an increase in striatal dopamine concentrations and a rescue of forelimb akinesia and spontaneous rotations. Phenotypic analysis using multiplexed iterative immunofluorescence imaging further revealed that most of these TH-positive cells co-expressed the dopaminergic marker DAT and the pan-neuronal marker NEUN, with the majority of these triple-positive cells being classified as mature GABAergic neurons. Additional research is needed to fully elucidate the molecular mechanisms underlying the expression of the observed markers and understand how the formation of these cells contributes to the rescue of spontaneous motor behaviors. Nevertheless, our findings support a model where downregulation of neuronal, but not astrocytic, PTBP1 can mitigate symptoms in PD mice.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Institute of Pharmacology and Toxicology, University of Zurich, Zurich, Switzerland.
- Division of Clinical Chemistry and Biochemistry, University Children's Hospital Zurich, University of Zurich, Zurich, Switzerland.
- Division of Metabolism and Children's Research Center, University Children's Hospital Zurich, Zurich, Switzerland.
- Neuroscience Center Zurich, University of Zurich and ETH Zurich, Zurich, Switzerland.
ORCID-Profile: Desiree Böck, Tommaso Patriarchi, Gerald Schwank
Förderung
- Swiss National Science Foundation
- Novartis Foundation for Medical-Biological Research
- European Research Council
- Helmut Horten Stiftung
- URPP Itinerare
Zitieren
APA
Böck, D., Wilhelm, M., Mumenthaler, J., Carpanese, D. F., Kulcsár, P. I., d'Aquin, S., Cremonesi, A., Rassi, A., Häberle, J., Patriarchi, T., & Schwank, G. (2024). Base editing of Ptbp1 in neurons alleviates symptoms in a mouse model of Parkinson’s disease. eLife. https://doi.org/10.7554/elife.97180
Vancouver
Böck D, Wilhelm M, Mumenthaler J, Carpanese DF, Kulcsár PI, d'Aquin S, et al. Base editing of Ptbp1 in neurons alleviates symptoms in a mouse model of Parkinson’s disease. eLife. 2024. doi:10.7554/elife.97180
BibTeX
@article{Bck2024,
author = {Böck, Desiree and Wilhelm, Maria and Mumenthaler, Jonas and Carpanese, Daniel Fabio and Kulcsár, Peter I and d'Aquin, Simon and Cremonesi, Alessio and Rassi, Anahita and Häberle, Johannes and Patriarchi, Tommaso and Schwank, Gerald},
title = {Base editing of Ptbp1 in neurons alleviates symptoms in a mouse model of Parkinson’s disease},
journal = {eLife},
year = {2024},
doi = {10.7554/elife.97180}
}
EUVIMED